Methylnaphthidate

Methylnaphthidate's potent dopamine and (inferred) norepinephrine reuptake inhibition elevates catecholamine tone systemically, increasing heart rate, blood pressure, and peripheral vasoconstriction. In individuals with compromised cardiovascular function — including coronary artery disease, heart failure, arrhythmias, or uncontrolled hypertension — these effects pose acute risk of cardiac ischemia, arrhythmia, and stroke.

Potent DAT/NET reuptake inhibitors lower the seizure threshold through excessive catecholaminergic stimulation. Individuals with epilepsy or other seizure disorders face elevated risk of breakthrough seizures. The SERT component may compound this risk at high doses.

DAT inhibition elevates mesolimbic dopamine, which can trigger psychotic symptoms (paranoid ideation, hallucinations, disorganized behavior) or precipitate manic episodes in individuals with bipolar disorder. This risk is well-established for the stimulant class and expected to apply to methylnaphthidate given its high DAT potency (IC₅₀ 33.9 nM racemic).

Monoamine oxidase inhibitors prevent the enzymatic degradation of dopamine, norepinephrine, and serotonin. When combined with methylnaphthidate's triple reuptake inhibition — particularly its significant SERT activity (IC₅₀ 71.6 nM) — the resulting accumulation of synaptic monoamines can trigger hypertensive crisis and serotonin syndrome, both potentially fatal.

Methylnaphthidate's significant SERT activity (IC₅₀ 71.6 nM) — unusual among phenidates — creates additive serotonergic risk when combined with SSRIs, SNRIs, triptans, or other serotonergic agents. The DAT/SERT discrimination ratio of ~4.8 means SERT inhibition occurs at doses close to those producing dopaminergic effects, making clinically relevant serotonin elevation likely at common doses.